Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.875
Bid: 2.75
Ask: 3.00
Change: 0.00 (0.00%)
Spread: 0.25 (9.091%)
Open: 2.875
High: 3.00
Low: 2.875
Prev. Close: 2.875
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification under AIM Rule Schedule Two (g)

9 Oct 2013 08:48

RNS Number : 0827Q
Allergy Therapeutics PLC
09 October 2013
 



9 October 2013

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Notification under AIM Rule Schedule Two (g)

 

Allergy Therapeutics plc (AIM: AGY), the specialist pharmaceutical company focused on allergy vaccination, makes the following update announcement under AIM Rule Schedule Two (g) regarding Stephen Smith, a non-executive director of Allergy Therapeutics plc.

 

In addition to being a non-executive director of the Company, Stephen Smith acts as a 'company doctor' working with companies in distressed situations and in some cases the role has required a restructuring through a pre-planned administration/receivership or a planned insolvency to ensure an orderly winding down of the business. In providing these services, Stephen Smith was appointed as a director of the companies listed below in Table 1 which had administrators, receivers or liquidators appointed. These companies were part of the following groups:

 

· Texon International Group where Stephen Smith was appointed a director in 2004 and subsequently there was a restructuring in 2005 through a receivership which created a viable group where he continues to be a director.

 

· Ethel Austin Group where Stephen Smith was appointed a director in 2005. In 2008 lenders sold their secured loans to a company which appointed administrators a few days later.

 

· The Food & Drink Group where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 in a pre-planned process to achieve a sale of the profitable parts of the business.

 

· Paramount Restaurants Group where Stephen Smith was appointed a director in 2011 and later that year arranged a restructuring and subsequent pre-planned administration to achieve disposals of the profitable parts of the group.

 

· Ennstone plc where Stephen Smith was appointed a director in 2008 and administrators were appointed in 2009 to complete a restructuring which ensured the viability of the UK and European businesses and protected the US business via a Chapter 11 process.

 

Table 1

 

Company

Comments

ACLM Limited (in administration)

Part of Ethel Austin Group

Bluelodge Limited (in administration)

Part of The Food & Drink Group

Burlington Restaurant Limited (in administration)

Part of The Food & Drink Group

Ennstone plc (in administration)

Holding company

Enterprises Realisations Limited (in administration)

Part of The Food & Drink Group

Ethel Austin Retail Group Limited (in administration)

Part of Ethel Austin Group

Ethel Austin Retail Holdings Limited (in administration)

Part of Ethel Austin Group

Futurestar Limited (in administration)

Part of The Food & Drink Group

Group Realisations Limited (in administration)

Part of The Food & Drink Group

Hartford Operations Limited (in administration)

Part of The Food & Drink Group

J Bar Limited (in administration)

Part of The Food & Drink Group

Montana plc (in administration)

Part of The Food & Drink Group

Newtaste Restaurants Limited (in administration)

Part of The Food & Drink Group

Noteframe Limited (in administration)

Part of Ethel Austin Group

Noxet Administration Services Limited

Part of Texon International group

PWC Realisations Limited (in administration)

Part of The Food & Drink Group

Texon Group Limited

Part of Texon International group

Texon Holdings Ltd (in liquidation)

Part of Texon International group

Texon International Limited

Part of Texon International group

The Food & Drink Group plc (in administration)

Part of The Food & Drink Group

USM (Holdings) Ltd

Part of Texon International group

Vantis Financial Management Limited (in administration)

Part of Vantis group

Vantis plc (in administration)

Part of Vantis group

Caffe Uno Brasseries Limited (in administration)

Part of Paramount Restaurants group

Charlotte Street Restaurants Limited

Part of Paramount Restaurants group

Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Craftbutton Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Limited (in administration)

Part of Paramount Restaurants group

Groupe Chez Gerard Restaurants Limited (in administration)

Part of Paramount Restaurants group

Leviathan Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Acquisitions Limited (in liquidation)

Part of Paramount Restaurants group

Paramount Holdings Limited (in administration)

Part of Paramount Restaurants group

Paramount Limited (in administration)

Part of Paramount Restaurants group

Paramount Restaurants Limited (in administration)

Part of Paramount Restaurants group

Smile Restaurants Limited (in liquidation)

Part of Paramount Restaurants group

 

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 821

Ian Postlethwaite

Finance Director

Manuel Llobet

Chief Executive Officer

www.allergytherapeutics.com

Peel Hunt LLP

+44 (0) 20 7418 8900

James Steel / Dr. Vijay Barathan

FTI Consulting

+44 (0) 207 831 3113

Simon Conway / Victoria Foster Mitchell

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFSDIRLAIIV
Date   Source Headline
3rd Apr 20247:00 amRNSDirector Resignation
27th Mar 20247:00 amRNSUpdate on funding
27th Mar 20247:00 amRNSInterim Results for six months ended 31 Dec 2023
12th Mar 20248:59 amRNSVLP Peanut PROTECT Trial Update
12th Mar 20247:00 amRNSVLP Peanut PROTECT Trial Update
11th Mar 20247:00 amRNSAppointment of Shaun Furlong to Board of Directors
8th Mar 20241:49 pmRNSResult of AGM
14th Feb 20247:00 amRNSHalf-Year Trading Update 2024
9th Feb 20243:07 pmRNSNotice of 2023 Annual General Meeting
30th Jan 20247:30 amRNSRestoration - Allergy Therapeutics plc
30th Jan 20247:00 amRNSPublication of Annual Report and Accounts 2023
4th Jan 202412:29 pmRNSTotal Voting Rights
2nd Jan 20247:30 amRNSSuspension - Allergy Therapeutics plc
27th Dec 202312:01 pmRNSAmendment to existing Facility Agreement
15th Dec 202312:48 pmRNSAnnual Report and Accounts Delayed
13th Dec 20234:54 pmRNSPDMR dealing and Total Voting Rights
13th Dec 20237:00 amRNSG306 Phase III trial meets key endpoints
11th Dec 20237:00 amRNSUpdate on funding
1st Dec 20237:00 amRNSTotal Voting Rights
28th Nov 20233:03 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSG306 Grass Phase III trial meets primary endpoint
10th Nov 20232:39 pmRNSForm 8.5 (EPT/RI)
10th Nov 20231:22 pmRNSDirector/PCA Dealing
10th Nov 20231:11 pmRNSHolding(s) in Company
10th Nov 20237:00 amRNSOffer Closure
9th Nov 202310:48 amRNSExercise of Options and Total Voting Rights
9th Nov 20239:24 amRNSForm 8.5 (EPT/RI)
9th Nov 20239:15 amRNSForm 8.5 (EPT/NON-RI)
8th Nov 202310:45 amRNSForm 8.5 (EPT/RI)
7th Nov 202311:10 amRNSForm 8.5 (EPT/RI)
6th Nov 20239:33 amRNSForm 8.5 (EPT/RI)
6th Nov 20237:00 amRNSUpdate on funding
3rd Nov 20239:31 amRNSForm 8.5 (EPT/RI)
2nd Nov 202310:24 amRNSForm 8.5 (EPT/RI)
1st Nov 202310:23 amRNSForm 8.5 (EPT/RI)
31st Oct 20238:30 amRNSForm 8.5 (EPT/RI)
30th Oct 202310:06 amRNSForm 8.5 (EPT/RI)
27th Oct 202311:33 amRNSForm 8.5 (EPT/RI)
26th Oct 202310:07 amRNSForm 8.5 (EPT/RI)
25th Oct 20239:48 amRNSForm 8.5 (EPT/NON-RI)
25th Oct 20238:43 amRNSForm 8.5 (EPT/RI)
24th Oct 20238:29 amRNSForm 8.5 (EPT/RI)
23rd Oct 20238:23 amRNSForm 8.5 (EPT/RI)
20th Oct 20235:17 pmRNSHolding(s) in Company
20th Oct 20239:02 amRNSForm 8.5 (EPT/RI)
19th Oct 20238:38 amRNSForm 8.5 (EPT/RI)
19th Oct 20237:00 amRNSPosting of Offer Document
18th Oct 20238:34 amRNSForm 8.5 (EPT/RI)
17th Oct 202310:31 amRNSForm 8.5 (EPT/RI)
16th Oct 20235:39 pmRNSSouthern Fox: Form 8.3 – Allergy Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.